Table 1

Schedule of enrolment, interventions and assessments

Study period
 Eligibility screenX
 Informed consentX
 Baseline featuresXX
 Safety eligibility testsXX
 Fasting phlebotomy for study parametersXX
 Assessment of HRQoLsXX
  • Baseline features include HOMA-IR (primary outcome), hormonal profiles (T, AND, SHBG, DHEAS, FSH, LH, E2), weight, waist/hip circumference, BMI, blood pressure, FG score and acne. Safety eligibility includes liver function, renal function and complete blood count. t0, enrolment; t1, 1 month after allocation; t2, 2 months after allocation; t3, 3 months after allocation, t4, the beginning of the fourth month after allocation.

  • AA, auricular points acupressure; AND, androstadienedione; BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; E2, estradiol; FG, Ferriman-Gallwey; FSH, follicle-stimulating hormone; HOMA-IR, homeostatic model assessment ; HRQoL, health-related quality of life; LH, luteinising hormone; SHBG, sex hormone-binding globulin; T, testosterone.